“As a scientist trained in the late 1970s and early 1980s, with decades of experience in both academia and the pharmaceutical and biotechnology industries, I would suggest that Allysia Finley's column on the employment challenges arising from an oversupply of humanities Ph.D.s could be extended to include graduates of doctoral programs focused on the natural sciences ("The Ph.D. Job Crisis Is a Needed Market Correction," Life Science, Sept. 28).
In biomedical science and drug discovery, Ph.D. graduates can face several obstacles to applying their expertise to the development of new therapeutics. In academia, an aging tenured faculty, persistent uncertainty over government research funding, and a power imbalance that can reduce Ph.D. trainees to relatively inexpensive labor for advancing faculty careers can undermine both doctoral training and admissions.
Meanwhile, the private-sector pharmaceutical and biotechnology industries are retrenching amid rising R&D costs, tariff threats, intensifying commercial competition, heightened regulatory scrutiny and the looming expiration of patents on top-selling drugs. Together, these pressures have made it increasingly difficult for science Ph.D.s to apply their talents. Instead, many find themselves caught in what I call a "perpetual postdoc syndrome," moving from one position in someone else's academic laboratory to another without a clear path to independent research.
Potential risks from this scenario: fewer research practitioners to address unsolved medical problems with innovative therapeutics and fewer experienced discovery scientists to teach and mentor future drug hunters, regardless of enabling technological advances. It's time to examine a market correction for STEM Ph.D.s -- one that serves both their career prospects and public health.
David R. Janero
Boston” [1]
1. We Have to Fix 'Perpetual Postdoc Syndrome'. Wall Street Journal, Eastern edition; New York, N.Y.. 06 Oct 2026: A14.
Komentarų nėra:
Rašyti komentarą